首页> 外文会议>International symposium on controlled release of bioactive materials;Consumer and diversified products conference >Controlled release of insulin from biodegradable microcapsules following a single subcutaneous administration to streptozotocin-induced diabetes rats
【24h】

Controlled release of insulin from biodegradable microcapsules following a single subcutaneous administration to streptozotocin-induced diabetes rats

机译:对链脲佐菌素诱发的糖尿病大鼠单次皮下给药后,从可生物降解的微胶囊中控制释放胰岛素

获取原文

摘要

For the treatment of insulin dependent-diabetes mellitus (IDDM), insulin therapy by injectable formulation is common and necessary to lower the high blood glucose level. A steady insulin level is also necessary to maintain homeostasis in patients. However, they have to take multiple treatments even when the insulin formulation characterized by a sustained release was applied. Therefore, it would be desirable to develop a prolonged releasing system of insulin. In order to achieve this purpose, we have bene studying to prepare a microcapsule system from which could prolong the release of insulin without initial burst release. We incorporated insulin into an injectable, biodegradable polymer composed of co-poly (D,L-lactic/glycolic) acid (PLGA) which ratio was 50:50 and molecular weight was 8,000. Several kinds of microcapsules containing human insulin were tested using streptozotocin-induced hyperglycemia rats.
机译:为了治疗胰岛素依赖型糖尿病(IDDM),通过注射制剂进行胰岛素治疗是常见的,并且对于降低高血糖水平是必要的。维持患者体内稳态也需要稳定的胰岛素水平。然而,即使应用以持续释放为特征的胰岛素制剂,它们也必须采取多种治疗。因此,需要开发胰岛素的延长释放系统。为了达到这个目的,我们进行了研究以制备一种微胶囊系统,该系统可以延长胰岛素的释放而无需最初的突释。我们将胰岛素掺入由比例为50:50,分子量为8,000的共聚(D,L-乳酸/乙醇酸)(PLGA)组成的可注射,可生物降解的聚合物中。使用链脲佐菌素诱导的高血糖大鼠测试了几种含有人胰岛素的微胶囊。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号